论文部分内容阅读
通过药物促进胎儿肺成熟的观点是由Avery等提出的,他们证明肾上腺糖皮质激素能促进肺表面活性物质的产生。肾上腺糖皮质激素通过成纤维细胞产生叫做成纤维细胞肺泡因子(FPF)的一种肺生长因子,作用于Ⅱ型肺泡上皮,增强肺表面活性磷脂和脱辅基蛋白合成酶的活性。最近,也有报告认为肺表面活性物质的贮量增加没有意义,而与整个肺脏机能成熟的程度有关。把预防因肺发育不成熟,缺少肺表面活性物质为病因的RDS的发生为指标,自Liggins等试用以
The idea of drug promotion of fetal lung maturation was suggested by Avery et al. Who demonstrated that adrenal glucocorticoids promote the production of pulmonary surfactant. Glucocorticoids produce a type of pulmonary growth factor called fibroblast alveolar factor (FPF) via fibroblasts that act on type II alveolar epithelium and enhance pulmonary surfactant phosphoprotein and apoprotein synthase activity. Recently, it has also been reported that there is no point in increasing the storage volume of pulmonary surfactant, but rather with the degree of maturation of the entire lung. The prevention of immature due to lung development, the lack of pulmonary surfactant as the cause of the occurrence of RDS as an indicator since Liggins and other trials to